Paragraph IV Disputes

The APJs Speak on Practice, Policy, and Procedure in the World of Pharmaceutical Patent Validity Challenges

April 30, 2019 • 9:15 am

Honorable Jacqueline Wright Bonilla

Vice Chief, Administrative

Patent Judge

April 30, 2019 • 1:00 pm

Honorable Christopher J. Burke

Magistrate Judge

District of Delaware

April 30, 2019 • 9:15 am

Honorable Renee M. Bumb

United States District Judge

District of New Jersey

April 29, 2019 • 5:15 pm

Honorable Ruben Castillo

United States District Court

Norther District of Illinois (Chicago, IL)

April 29, 2019 • 5:15 pm

Honorable Stanley R. Chesler

United States District Judge

District of New Jersey (Newark, NJ)

The APJs Speak on Practice, Policy, and Procedure in the World of Pharmaceutical Patent Validity Challenges

April 29, 2019 • 5:15 pm

Honorable Rama G. Elluru

Administrative Patent Judge

April 30, 2019 • 1:00 pm

Honorable Kathleen M. O’Malley

United States Circuit Judge

United States Court of Appeals for the Federal Circuit (Washington, DC)

VIEW FROM THE FEDERAL CIRCUIT

April 29, 2019 • 10:30 am

Honorable Roy Payne

Magistrate Judge

Eastern District of Texas (Marshall, TX)

April 30, 2019 • 9:15 am

Honorable Mary Pat Thynge

Chief Magistrate Judge

District of Delaware (Wilmington, DE)

Antitrust Developments Concerning Brands & Generics

April 30, 2019 • 9:15 am

Government Representatives

Markus H. Meier

Acting Director, Bureau of Competition

Federal Trade Commission (Washington, DC)

April 30, 2019 • 11:30 am

Grail Sipes

Deputy Center Director, Regulatory Policy

CDER

Latest FDA Initiatives Affecting Generic Drug Access and Pricing

April 30, 2019 • 8:15 am

Maryll Toufanian

Director Office of Generic Drug Policy, CDER

U.S. Food & Drug Administration (Silver Spring, MD)

Latest FDA Initiatives Affecting Generic Drug Access and Pricing

April 30, 2019 • 8:15 am

In-House Counsel

Andrew Allen

Director, Legal Counsel, IP

Dr. Reddy’s Labs

Subject Matter Patentability and Written Description Reconsidered: Understanding the New §101 and §112 Conundrum

April 29, 2019 • 4:15 pm

Tashica Williams Amirgholizadeh

Patent Litigation Counsel

Gilead Sciences

Brian Anderson

VP & Assistant General Counsel, IP Litigation

Allergan

ACI’s Hatch-Waxman Series Advisory Board on “The Three C’s*

April 29, 2019 • 2:00 pm

Phil Carey

Senior Counsel, Patent Litigation

Sandoz

The Business of Pharmaceutical Patent Litigation: A Global Approach

April 29, 2019 • 2:00 pm

Karen Day

Senior Counsel

Pfizer (New York, NY)

New Developments in Market Access and Exclusivities

April 30, 2019 • 9:15 am

Stephanie L. Donahue

Senior Director, Patent Litigation

Sanofi (Bridgewater, NJ)

ACI’s Hatch-Waxman Series Advisory Board on “The Three C’s*

April 29, 2019 • 2:00 pm

Rekha Hanu, Ph.D, J.D

Executive Director, Chief IP Counsel

Akorn Pharmaceuticals (Lake Forest, IL)

ACI’s Hatch-Waxman Series Advisory Board on “The Three C’s*

April 29, 2019 • 2:00 pm

Brian Hirsch

Vice President Global IP and Legal Head North America

Glenmark Pharmaceuticals (Mahwah, NJ)

ACI’s Hatch-Waxman Series Advisory Board on “The Three C’s*

April 29, 2019 • 2:00 pm

Serge Ilin-Schneider

General Counsel

Wockhardt USA & Morton Grove Pharmaceuticals (Troy Hills, NJ)

The Business of Pharmaceutical Patent Litigation: A Global Approach

April 29, 2019 • 2:00 pm

Lisa Jakob

Managing Counsel, Trademark Group

Merck (Rahway, NJ)

ACI’s Hatch-Waxman Series Advisory Board on “The Three C’s*

April 29, 2019 • 2:00 pm

Staci Julie

SVP and Chief IP Counsel

Teva Pharmaceuticals (Horsham, PA)

ACI’s Hatch-Waxman Series Advisory Board on “The Three C’s*

April 29, 2019 • 2:00 pm

Bruce J. Koch

Associate General Counsel, Head of Patent Litigation

Purdue Pharma L.P. (Stamford, CT)

The Practice of Pharmaceutical Patent Litigation: Part II

April 30, 2019 • 9:15 am

Josephine Liu, Ph.D., J.D.

Head, US IP Litigation

Sandoz Inc. (Princeton, NJ)

ACI’s Hatch-Waxman Series Advisory Board on “The Three C’s*

April 29, 2019 • 2:00 pm

Brian McCormick

Vice President – Chief Regulatory Counsel

Teva Pharmaceuticals (Horsham, PA)

New Developments in Market Access and Exclusivities

April 30, 2019 • 9:15 am

Jennifer Grant Moitoso

VP, IP

Shire

ACI’s Hatch-Waxman Series Advisory Board on “The Three C’s*

April 29, 2019 • 2:00 pm

Sam Park

U.S. General Counsel and Global Head of IP

Hikma Pharmaceuticals

The Ethical Practice of Paragraph IV Litigation: New Developments Impacting Professional Responsibility in the Hatch-Waxman Arena

April 30, 2019 • 3:15 pm

Marck Rachlin

Senior Patent Counsel

GSK (King of Prussia, PA)

April 30, 2019 • 4:00 pm

Colman Ragan

VP & General Counsel, North America IP Litigation

Teva Pharmaceuticals

The Practice of Pharmaceutical Patent Litigation: Part I

April 29, 2019 • 2:00 pm

Lars Taavola

Senior Patent Counsel – Global IP, Head of Patent Litigation

Amneal Pharmaceuticals

The Costs and the Consequences of Determining Venue Post-TC Heartland

April 29, 2019 • 1:00 pm

Laura A. Vogel

Senior Dir., Assoc. General Counsel of IP

Tesaro, Inc.

The Practice of Pharmaceutical Patent Litigation: Part II

April 30, 2019 • 9:15 am

Kevin Zive

VP, Global IP

Apotex (Toronto, ON)

The Business of Pharmaceutical Patent Litigation: A Global Approach

April 29, 2019 • 2:00 pm

Law Firm Attorneys

David B. Abramowitz

Partner

Locke Lord LLP (Chicago, IL)

New Developments in Market Access and Exclusivities

April 30, 2019 • 9:15 am

Richard J. Berman

Partner

Arent Fox LLP (Washington, DC)

The Costs and the Consequences of Determining Venue Post-TC Heartland

April 29, 2019 • 1:00 pm

Aziz Burgy

Partner

Axinn, Veltrop & Harkrider LLP (Washington, DC)

April 30, 2019 • 9:15 am

Kathleen B. Carr

Partner

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Assessing Secondary Considerations in Light of Blocking Patents Post-Acorda

April 29, 2019 • 5:15 pm

Alan B. Clement

Partner

Locke Lord LLP (New York, NY)

April 30, 2019 • 2:00 pm

David G. Conlin

Member

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (Boston, MA)

The Ethical Practice of Paragraph IV Litigation: New Developments Impacting Professional Responsibility in the Hatch-Waxman Arena

April 30, 2019 • 4:00 pm

Steven M. Coyle

Partner

Cantor Colburn LLP (Hartford, CT)

Addressing the Impact of a Uniform Claims Construction Standard: Panacea or Peril?

April 29, 2019 • 9:15 am

Carol Pitzel Cruz

Partner

Knobbe Martens (Seattle, WA)

Bo Davis

Founding Partner

The Davis Firm (Longview, TX)

The Practice of Pharmaceutical Patent Litigation: Part I

April 30, 2019 • 9:15 am

Daniel P. DiNapoli

Partner

Arnold & Porter LLP (New York, NY)

April 29, 2019 • 2:00 pm

Michael Dougherty

Partner

DLA Piper (New York, NY)

The Practice of Pharmaceutical Patent Litigation: Part II

April 30, 2019 • 3:15 pm

Laura Fairneny

Partner

Quinn Emanuel Urquhart & Sullivan, LLP (New York, NY)

April 30, 2019 • 9:15 am

Gerald J. Flattmann Jr.

Partner

King & Spalding (New York, NY)

Subject Matter Patentability and Written Description Reconsidered: Understanding the New §101 and §112 Conundrum

April 29, 2019 • 4:15 pm

Christine I. Gannon

Partner

Walsh Pizzi O’Reilly Falanga LLP (Newark, NJ)

Jeffrey R. Gargano

Partner

Morgan, Lewis & Bockius LLP (Chicago, IL)

Parallel Proceedings Master Class

May 1, 2019 • 1:00 pm

Anne Shea Gaza

Partner

Young Conaway Stargartt & Taylor, LLP (Wilmington, DE)

April 30, 2019 • 9:15 am

Barry P. Golob

Co-Chair, Intellectual Property Litigation

Cozen O’Connor

The Present State of Paragraph IV Litigation and Its Impact on the Pharmaceutical Industry: Legal Analyses and Business Prognoses

April 29, 2019 • 5:15 pm

Taras A. Gracey

Shareholder

Polsinelli PC (Chicago, IL)

April 29, 2019 • 8:15 am

Vishal C. Gupta

Partner

Steptoe & Johnson LLP (New York, NY)

The Practice of Pharmaceutical Patent Litigation: Part I

April 29, 2019 • 2:00 pm

John T. Gutkoski

Partner

McCarter & English, LLP (Boston, MA)

Sheldon Hamilton

Partner

Smart & Biggar Fetherstonhaugh (Toronto, ON)

The Practice of Pharmaceutical Patent Litigation: Part I

April 29, 2019 • 2:00 pm

Gary E. Hood

Shareholder, IP Division Chair

Polsinelli PC (Chicago, IL)

The Practice of Pharmaceutical Patent Litigation: Part II

April 30, 2019 • 9:15 am

Benjamin C. Hsing

Partner

McGuire Woods (New York, NY)

The Practice of Pharmaceutical Patent Litigation: Part II

April 30, 2019 • 9:15 am

Charlotte Jacobsen

Partner

Ropes & Gray LLP (New York, NY)

The Present State of Paragraph IV Litigation and Its Impact on the Pharmaceutical Industry: Legal Analyses and Business Prognoses

April 29, 2019 • 8:15 am

Michael P. Kahn

Partner

Akin Gump Strauss Hauer & Feld LLP (New York, NY)

Addressing the Impact of a Uniform Claims Construction Standard: Panacea or Peril?

April 29, 2019 • 9:15 am

Scott E. Kamholz

Of Counsel

Covington & Burling LLP (Washington, DC)

Kurt R. Karst

Director

Hyman, Phelps & McNamara PC (Washington, DC)

Ben Katzenellenbogen

Partner

Knobbe Martens (Irvine, CA)

The Supreme Court Weighs in on the On- Sale Bar and the State of Secret Prior Art

April 29, 2019 • 11:00 am

Nathaniel Lipkus

Partner

Osler, Hoskin & Harcourt LLP

The Business of Pharmaceutical Patent Litigation: A Global Approach

April 29, 2019 • 2:00 pm

Aaron Lukas

Member

Cozen O’Connor (Washington, DC)

Addressing the Impact of a Uniform Claims Construction Standard: Panacea or Peril?

April 29, 2019 • 9:15 am

Emily Marden

Counsel

Sidley Austin LLP

New Developments in Market Access and Exclusivities

April 30, 2019 • 9:15 am

Christie Matthaei

Partner

Knobbe Martens (Seattle, WA)

The Practice of Pharmaceutical Patent Litigation: Part II

April 30, 2019 • 9:15 am

Daniel J. Minion

Partner

Fitzpatrick, Cella, Harper & Scinto

ACI’s Hatch-Waxman Series Advisory Board on “The Three C’s*

April 30, 2019 • 3:15 pm

John Molenda

Partner

Steptoe & Johnson LLP (New York, NY)

April 29, 2019 • 2:00 pm

Gregory A. Morris

Partner

Honigman LLP (Chicago, IL)

The Costs and the Consequences of Determining Venue Post-TC Heartland

April 29, 2019 • 1:00 pm

Deepro R. Mukerjee

Partner

KattenMuchinRosenman LLP (New York, NY)

The Business of Pharmaceutical Patent Litigation: A Global Approach

April 29, 2019 • 2:00 pm

Huong Nguyen

Partner

Litwin Law LLC (Oakland, CA)

The Practice of Pharmaceutical Patent Litigation: Part I

April 29, 2019 • 2:00 pm

Kevin E. Noonan

Partner

McDonnell Boehnen Hulbert & Berghoff LLP (Chicago, IL)

Working Group on Biosimilars for the Hatch-Waxman Practitioner

May 1, 2019 • 8:30 am

Joseph O’Malley

Partner

Paul Hastings LLP (New York, NY)

The Supreme Court Weighs in on the On- Sale Bar and the State of Secret Prior Art

April 29, 2019 • 11:00 am

Sapna W. Palla

Partner

Wiggin and Dana (New York, NY)

New Developments in Market Access and Exclusivities

April 30, 2019 • 9:15 am

Matthew A. Pearson

Partner

Akin Gump Strauss Hauer & Feld LLP (Philadelphia, PA)

Subject Matter Patentability and Written Description Reconsidered: Understanding the New §101 and §112 Conundrum

April 29, 2019 • 4:15 pm

Lisa B. Pensabene

Partner

O’Melveny & Myers LLP (New York, NY)

The Present State of Paragraph IV Litigation and Its Impact on the Pharmaceutical Industry: Legal Analyses and Business Prognoses

April 29, 2019 • 8:15 am

Liane M. Peterson

Partner

Foley & Lardner LLP (Washington, DC)

Assessing Secondary Considerations in Light of Blocking Patents Post-Acorda

April 30, 2019 • 2:00 pm

Filko Prugo

Partner

Ropes & Gray LLP (New York, NY)